Last checked at 25 Oct 2022 14:30
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION OF THE CIRCULAR TO SHAREHOLDERS OF THE COMPANY DATED 7 OCTOBER 2022.
Oxford BioDynamics PLC
("OBD", the "Company" or together with its subsidiaries, the "Group")
Result of Open Offer
Change to Rump Placing Timetable
Oxford, UK - 25 October 2022 Oxford BioDynamics.Plc (AIM: OBD), a biotechnology company developing targeted clinical diagnostic tests for immune health based on the EpiSwitch® 3D genomics platform, is pleased to announce the result of the Open Offer as part of the Placing, Subscription and Open Offer announced on 7 October 2022.
The Company has received valid acceptances from Qualifying Shareholders in respect of 1,082,806 Open Offer Shares.
All Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full entitlements. Accordingly, the Open Offer has conditionally raised total gross proceeds of approximately £216,561, with a total of £9.3 million having been conditionally raised via the Placing, Subscription and Open Offer.
The Brokers will use their reasonable endeavours to place any Unsubscribed Open Offer Shares at the Issue Price pursuant to the Rump Placing. It is envisaged that any Unsubscribed Open Offer Shares placed under the Rump Placing would be admitted alongside the VCT/EIS Shares at 8.00 a.m. on Friday, 28 October 2022 or the General Placing Shares, Subscription Shares and Open Offer Shares at8.00 a.m. on Monday, 31 October 2022, as appropriate, rather than 7 November 2022 as previously announced. A further announcement on the result of the Rump Placing will be made in due course.
The issue of the new Ordinary Shares pursuant to the Placing, Subscription, Open Offer and Rump Placing is subject to and conditional on the passing of the Resolutions at the General Meeting to be held on Thursday, 27 October 2022.
For further details please contact:
Oxford BioDynamics PLC Jon Burrows, CEO Paul Stockdale, CFO | Tel: +44 (0)1865 518910
| |
Shore Capital (Nominated Adviser and Broker) Stephane Auton John More |
Tel: +44 (0)20 7408 4090
| |
Instinctif Partners Melanie Toyne-Sewell Agnes Stephens Katie Duffell Jonjo Cordey |
Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com
| |
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.